Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2006

Open Access 01-12-2006 | Research article

In vitro modulation of inflammatory cytokine and IgG levels by extracts of Perna canaliculus

Authors: Sachin Mani, John W Lawson

Published in: BMC Complementary Medicine and Therapies | Issue 1/2006

Login to get access

Abstract

Background

Inflammation is a predominant characteristic of autoimmune diseases which is characterized by the increased expression of pro-inflammatory cytokines. Soon to be published work from our laboratory has shown that ingestion of Perna canaliculus prevents the development of autoimmune diseases such as Systemic Lupus Erythematosus and rheumatoid arthritis in laboratory animals. The current paper attempts to illustrate how Perna can alleviate inflammation by modulating inflammatory cytokines, cyclooxygenase enzymes and Immunoglobulin-G (IgG) levels.

Methods

In the present study, hydrochloric acid [HCl] and Tween-20 were used to develop extracts of Perna. These extracts were assayed for protein content. Increasing concentrations of these extracts were then tested in cell culture for modulation of inflammatory cytokine, cyclooxygenase enzymes and IgG levels. Parallel tests were run using an available glycogen extract of Perna as a comparison to our in-house laboratory preparations.

Results

Tween-20 Perna extracts were found to be more stable and less toxic in cell culture than HCl digest of Perna. They also assayed higher in protein content that HCl extracts. Although both extracts inhibited IgG production in V2E9 hybridomas, Tween-20 extracts were more consistent in IgG suppression than HCl extracts. Overall Tween-20 extracts effectively decreased levels of TNF-α, IL-1, IL-2 and IL-6 as observed using cytokine bioassays. Twenty micrograms of Tween-20 Perna extracts induced such significant decreases in inflammatory cytokine production that when tested on sensitive cell lines, they very nearly abolished the decrease in viability induced by these cytokines. Tween-20 extracts effectively inhibited both COX-1 and COX-2 cyclooxygenase activity. As a comparison, the glycogen extract also demonstrated a similar though weaker effect on COX-1 and COX-2 enzymes. The active components of both extracts (Tween-20 and glycogen) were observed to possess molecular weights above 100 kDa. Although the anti-cytokine activity of the Tween-20 extract was destroyed by Proteinase-K treatment, the anti-COX-1 and anti-COX-2 activity of both the extracts were not sensitive to protease treatment.

Conclusion

We have successfully demonstrated modulation in the levels of inflammatory cytokines, cyclooxygenase enzymes and immunoglobulins by our in-house laboratory preparations of Perna canaliculus, whereby suggesting an immunomodulatory role of Perna canaliculus in regulating inflammation.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Szobor A, Mattyus A, Molnar J: Myasthenia gravis in childhood and adolescence. Report on 209 patients and review of the literature. Acta Paediatrica Hungarica. 1988, 29: 299-312.PubMed Szobor A, Mattyus A, Molnar J: Myasthenia gravis in childhood and adolescence. Report on 209 patients and review of the literature. Acta Paediatrica Hungarica. 1988, 29: 299-312.PubMed
3.
go back to reference Smiley JD, Moore SEJ: Molecular mechanisms of autoimmunity. American Journal of Medical Science. 1988, 295: 478-496.CrossRef Smiley JD, Moore SEJ: Molecular mechanisms of autoimmunity. American Journal of Medical Science. 1988, 295: 478-496.CrossRef
4.
go back to reference Mihara M, Ohsugi Y, Saito K, Miyai T, Togashi M, Ono S, Murakami S, Dobashi K, Hirayama F, Hamaoka T: Immunologic abnormality in NZB/NZW F1 mice. Thymus-independent occurrence of B cell abnormality and requirement for T cells in the development of autoimmune disease, as evidenced by an analysis of the athymic nude individuals. Journal of Immunology. 1988, 141: 85-90. Mihara M, Ohsugi Y, Saito K, Miyai T, Togashi M, Ono S, Murakami S, Dobashi K, Hirayama F, Hamaoka T: Immunologic abnormality in NZB/NZW F1 mice. Thymus-independent occurrence of B cell abnormality and requirement for T cells in the development of autoimmune disease, as evidenced by an analysis of the athymic nude individuals. Journal of Immunology. 1988, 141: 85-90.
5.
go back to reference Kioke T, Itoh Y, Ishii T, Ito I, Takabayashi K, Maruyama N, Tomioka H, Yoshida S: Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes. 1987, 36: 539-541.CrossRef Kioke T, Itoh Y, Ishii T, Ito I, Takabayashi K, Maruyama N, Tomioka H, Yoshida S: Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes. 1987, 36: 539-541.CrossRef
6.
go back to reference Hang L, Theofilopoulos AN, Dixon FJ: A spontaneous rheumatoid arthritis-like disease in MRL/l mice. Journal of Experimental Medicine. 1982, 155: 1690-1701. 10.1084/jem.155.6.1690.CrossRefPubMed Hang L, Theofilopoulos AN, Dixon FJ: A spontaneous rheumatoid arthritis-like disease in MRL/l mice. Journal of Experimental Medicine. 1982, 155: 1690-1701. 10.1084/jem.155.6.1690.CrossRefPubMed
7.
go back to reference Balkwill FR, Burke F: The cytokine network. Immunology Today. 1989, 10: 299-304. 10.1016/0167-5699(89)90085-6.CrossRefPubMed Balkwill FR, Burke F: The cytokine network. Immunology Today. 1989, 10: 299-304. 10.1016/0167-5699(89)90085-6.CrossRefPubMed
8.
go back to reference Dean GS, Tyrell-Price J, Crawley E, Isenberg DA: Cytokines and systemic lupus erythematosus. Annals of Rheumatic Diseases. 2000, 59: 243-251. 10.1136/ard.59.4.243.CrossRef Dean GS, Tyrell-Price J, Crawley E, Isenberg DA: Cytokines and systemic lupus erythematosus. Annals of Rheumatic Diseases. 2000, 59: 243-251. 10.1136/ard.59.4.243.CrossRef
9.
go back to reference Badolato R, Oppenheim JJ: Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthrits. Seminars in Arthritis and Rheumatology. 1996, 26: 526-538. 10.1016/S0049-0172(96)80041-2.CrossRef Badolato R, Oppenheim JJ: Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthrits. Seminars in Arthritis and Rheumatology. 1996, 26: 526-538. 10.1016/S0049-0172(96)80041-2.CrossRef
10.
go back to reference Paolieri F, Salmaso C, Battifora M, Montagna P, Pesce G, Bagnasco M, Richiusa P, Galluzzo A, Giordano C: Possible pathogenetic relevance of interleukin-1 beta in "destructive" organ-specific autoimmune disease (Hashimoto's thyroiditis). Annals of the New York Academy of Sciences. 1999, 876: 221-228.CrossRefPubMed Paolieri F, Salmaso C, Battifora M, Montagna P, Pesce G, Bagnasco M, Richiusa P, Galluzzo A, Giordano C: Possible pathogenetic relevance of interleukin-1 beta in "destructive" organ-specific autoimmune disease (Hashimoto's thyroiditis). Annals of the New York Academy of Sciences. 1999, 876: 221-228.CrossRefPubMed
11.
go back to reference Pelletier JP, Roughley PJ, DiBattista JA, McCollum R, Martel-Pelletier J: Are cytokines involved in osteoarthritic pathophysiology?. Seminars in Arthritis and Rheumatism. 1991, 20: 12-25. 10.1016/0049-0172(91)90024-T.CrossRefPubMed Pelletier JP, Roughley PJ, DiBattista JA, McCollum R, Martel-Pelletier J: Are cytokines involved in osteoarthritic pathophysiology?. Seminars in Arthritis and Rheumatism. 1991, 20: 12-25. 10.1016/0049-0172(91)90024-T.CrossRefPubMed
12.
go back to reference Miller TE, Ormrod D: The anti-inflammatory activity of Perna canaliculus (NZ green lipped mussel). The New Zealand Medical Journal. 1980, 92: 187-193.PubMed Miller TE, Ormrod D: The anti-inflammatory activity of Perna canaliculus (NZ green lipped mussel). The New Zealand Medical Journal. 1980, 92: 187-193.PubMed
13.
go back to reference Gibson RG, Gibson SL, Conway V, Chappell D: Perna canaliculus in the treatment of arthritis. Practitioner. 1980, 224: 955-960.PubMed Gibson RG, Gibson SL, Conway V, Chappell D: Perna canaliculus in the treatment of arthritis. Practitioner. 1980, 224: 955-960.PubMed
14.
go back to reference Gibson SL, Gibson RG: The treatment of arthritis with a lipid extract of Perna canaliculus: a random trial. Complementary Therapies in Medicine. 1998, 6: 122-126. 10.1016/S0965-2299(98)80003-4.CrossRef Gibson SL, Gibson RG: The treatment of arthritis with a lipid extract of Perna canaliculus: a random trial. Complementary Therapies in Medicine. 1998, 6: 122-126. 10.1016/S0965-2299(98)80003-4.CrossRef
15.
go back to reference Andeuval B, Bochacourt P: Controlled double-blind study of the mussel extract Perna canaliculus (green-lipped mussel) against a placebo in arthritis of the knee. Gazette Medicale. 1986, 93: 122-126 (French). Andeuval B, Bochacourt P: Controlled double-blind study of the mussel extract Perna canaliculus (green-lipped mussel) against a placebo in arthritis of the knee. Gazette Medicale. 1986, 93: 122-126 (French).
17.
go back to reference Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for asprin-like drugs. Nature New Biology. 1971, 231: 232-235.CrossRefPubMed Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for asprin-like drugs. Nature New Biology. 1971, 231: 232-235.CrossRefPubMed
18.
go back to reference Miller TE, Wu H: In vivo evidence for prostaglandin inhibitory activity in New Zealand green-lipped mussel extract. The New Zealand Medical Journal. 1984, 97: 355-357.PubMed Miller TE, Wu H: In vivo evidence for prostaglandin inhibitory activity in New Zealand green-lipped mussel extract. The New Zealand Medical Journal. 1984, 97: 355-357.PubMed
19.
go back to reference Ferreira SH, Vane JR: New aspects of the mode of action of nonsteroidal anti-inflammatory drugs. Annual Review of Pharmacology. 1974, 14: 57-73. 10.1146/annurev.pa.14.040174.000421.CrossRef Ferreira SH, Vane JR: New aspects of the mode of action of nonsteroidal anti-inflammatory drugs. Annual Review of Pharmacology. 1974, 14: 57-73. 10.1146/annurev.pa.14.040174.000421.CrossRef
20.
go back to reference Kosuge T, Tsuji K, Ishida H, Yamaguchi T: Isolation of an anti-histaminic substance from green-lipped mussel (Perna canaliculus). Chem Pharm Bull (Tokyo). 1986, 34: 4825-4828.CrossRef Kosuge T, Tsuji K, Ishida H, Yamaguchi T: Isolation of an anti-histaminic substance from green-lipped mussel (Perna canaliculus). Chem Pharm Bull (Tokyo). 1986, 34: 4825-4828.CrossRef
21.
go back to reference Whitehouse MW, Macrides TA, Kalafatis N, Betts WA, Haynes DR, Bradbert J: Anti-inflamatory activity of a lipid fraction (Lyprinol) from New Zealand green-lipped mussel. Inflammopharmacology. 1997, 5: 237-246.CrossRefPubMed Whitehouse MW, Macrides TA, Kalafatis N, Betts WA, Haynes DR, Bradbert J: Anti-inflamatory activity of a lipid fraction (Lyprinol) from New Zealand green-lipped mussel. Inflammopharmacology. 1997, 5: 237-246.CrossRefPubMed
22.
go back to reference Miller TE, Dodd J, Ormrod DJ, Geddes R: Anti-inflammatory activity of glycogen extracted from Perna canaliculus (NZ green-lipped mussel). Agents Actions. 1993, 38 Spec No: C139-42. 10.1007/BF01991164.CrossRefPubMed Miller TE, Dodd J, Ormrod DJ, Geddes R: Anti-inflammatory activity of glycogen extracted from Perna canaliculus (NZ green-lipped mussel). Agents Actions. 1993, 38 Spec No: C139-42. 10.1007/BF01991164.CrossRefPubMed
23.
go back to reference Caughey DE, Grigor RR, Caughey EB, Young P, Gow PJ, Stewart AW: Perna canaliculus in the treatment of rheumatoid arthritis. Eur J Rheumatol Inflamm. 1983, 6: 197-200.PubMed Caughey DE, Grigor RR, Caughey EB, Young P, Gow PJ, Stewart AW: Perna canaliculus in the treatment of rheumatoid arthritis. Eur J Rheumatol Inflamm. 1983, 6: 197-200.PubMed
24.
go back to reference Couch RA, Ormrod DJ, Miller TE, Watkins WB: Anti-inflammatory activity in fractionated extracts of the green-lipped mussel. The New Zealand Medical Journal. 1982, 95: 803-806.PubMed Couch RA, Ormrod DJ, Miller TE, Watkins WB: Anti-inflammatory activity in fractionated extracts of the green-lipped mussel. The New Zealand Medical Journal. 1982, 95: 803-806.PubMed
25.
go back to reference House RV: Cytokine bioassays: an overview. Developments in Biological Standardization. 1999, 97: 13-19.PubMed House RV: Cytokine bioassays: an overview. Developments in Biological Standardization. 1999, 97: 13-19.PubMed
26.
go back to reference Thorpe R, Wadhwa M, Page C, Mire-Sluis A: Bioassays for the characterization and control of theapeutic cytokines; determination of potency. Developments in Biological Standardization. 1999, 97: 61-71.PubMed Thorpe R, Wadhwa M, Page C, Mire-Sluis A: Bioassays for the characterization and control of theapeutic cytokines; determination of potency. Developments in Biological Standardization. 1999, 97: 61-71.PubMed
27.
go back to reference Mire-Sluis AR, Page L, Thorpe R: Quantitative cell line based bioassays for human cytokines. Journal of Immunological Methods. 1995, 187: 191-199. 10.1016/0022-1759(95)00220-1.CrossRefPubMed Mire-Sluis AR, Page L, Thorpe R: Quantitative cell line based bioassays for human cytokines. Journal of Immunological Methods. 1995, 187: 191-199. 10.1016/0022-1759(95)00220-1.CrossRefPubMed
28.
go back to reference Thorpe R, Wadhwa M, Bird CR, Mire-Sluis AR: Detection and measurment of cytokines. Blood Reviews. 1992, 6: 133-148. 10.1016/0268-960X(92)90025-L.CrossRefPubMed Thorpe R, Wadhwa M, Bird CR, Mire-Sluis AR: Detection and measurment of cytokines. Blood Reviews. 1992, 6: 133-148. 10.1016/0268-960X(92)90025-L.CrossRefPubMed
29.
go back to reference Tomkins P, Wadhwa M, Bird CR, Bowen G: The L929 cell bioassay for maurine tumor necrosis factor is not influenced by other murine cytokines. Journal of Immunological Methods. 1992, 151: 313-315. 10.1016/0022-1759(92)90133-E.CrossRefPubMed Tomkins P, Wadhwa M, Bird CR, Bowen G: The L929 cell bioassay for maurine tumor necrosis factor is not influenced by other murine cytokines. Journal of Immunological Methods. 1992, 151: 313-315. 10.1016/0022-1759(92)90133-E.CrossRefPubMed
30.
go back to reference Hay H, Cohen J: Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor. Journal of Clinical and Laboratory Immunology. 1989, 29: 151-155.PubMed Hay H, Cohen J: Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor. Journal of Clinical and Laboratory Immunology. 1989, 29: 151-155.PubMed
31.
go back to reference Keisari Y: A colorimetric microtiter assay for the quantitation of cytokine activity on adherent cells in tissue culture. Journal of Immunological Methods. 1992, 146: 155-161. 10.1016/0022-1759(92)90224-H.CrossRefPubMed Keisari Y: A colorimetric microtiter assay for the quantitation of cytokine activity on adherent cells in tissue culture. Journal of Immunological Methods. 1992, 146: 155-161. 10.1016/0022-1759(92)90224-H.CrossRefPubMed
32.
go back to reference Gieni RS, Li Y, HayGlass KT: Comparison of [3H] thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. Journal of Immunological Methods. 1995, 187: 85-83. 10.1016/0022-1759(95)00170-F.CrossRefPubMed Gieni RS, Li Y, HayGlass KT: Comparison of [3H] thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. Journal of Immunological Methods. 1995, 187: 85-83. 10.1016/0022-1759(95)00170-F.CrossRefPubMed
33.
go back to reference Goto M, Kirisawa R, Tajima M, Takahashi K, Iwai H: A bioassay for bovine interleukin-1 by the A375 cell inhibition. Journal of Vetrinary Medical Science. 1995, 57: 523-525. Goto M, Kirisawa R, Tajima M, Takahashi K, Iwai H: A bioassay for bovine interleukin-1 by the A375 cell inhibition. Journal of Vetrinary Medical Science. 1995, 57: 523-525.
34.
go back to reference Nakai S, Mizuno K, Kaneta M, Hirai Y: A simple, sensitive bioassay for the detection of interleukin-1 using human melanoma A375 cell line. Biochemical Biophysical Research Communications. 1988, 154: 541-548. Nakai S, Mizuno K, Kaneta M, Hirai Y: A simple, sensitive bioassay for the detection of interleukin-1 using human melanoma A375 cell line. Biochemical Biophysical Research Communications. 1988, 154: 541-548.
35.
go back to reference Pruett SB, Lackey A, Howell B, Ainsworth J: A quantitative, non-isotopic bioassay for inteleukin 2. Immunological Investigation. 1985, 14: 541-548.CrossRef Pruett SB, Lackey A, Howell B, Ainsworth J: A quantitative, non-isotopic bioassay for inteleukin 2. Immunological Investigation. 1985, 14: 541-548.CrossRef
36.
go back to reference Cernetti C, Steinman RM, Granelli-Piperno A: Bioassays for the detection of a cytokine that enhance the defelopment of cytolytic T lymphocytes. Cellular Immunology. 1987, 109: 148-158. 10.1016/0008-8749(87)90300-5.CrossRefPubMed Cernetti C, Steinman RM, Granelli-Piperno A: Bioassays for the detection of a cytokine that enhance the defelopment of cytolytic T lymphocytes. Cellular Immunology. 1987, 109: 148-158. 10.1016/0008-8749(87)90300-5.CrossRefPubMed
37.
go back to reference Pruett SB, Lackey A: Apparent interleukin 2 (IL-2) inhibitory activity of human serum is due to rapid killing of IL-2-dependent mouse cells. Clinical and Experimental Immunology. 1987, 69: 624-631.PubMedPubMedCentral Pruett SB, Lackey A: Apparent interleukin 2 (IL-2) inhibitory activity of human serum is due to rapid killing of IL-2-dependent mouse cells. Clinical and Experimental Immunology. 1987, 69: 624-631.PubMedPubMedCentral
38.
go back to reference Eskandari MK, Kunkel SL, Remick DG: Effects of arachidonic acid metabolites and other compounds on the CTLL assay for interleukin-2. Journal of Immunological Methods. 1989, 118: 85-99.CrossRefPubMed Eskandari MK, Kunkel SL, Remick DG: Effects of arachidonic acid metabolites and other compounds on the CTLL assay for interleukin-2. Journal of Immunological Methods. 1989, 118: 85-99.CrossRefPubMed
39.
go back to reference Papadopoulos NG, Dedoussis GV, Baxevanis CN, Papamichail M: Bioassay vs. immunoassay for quantification of interleukin-6 in biological fluids. Journal of Clinical Laboratory Analysis. 1995, 9: 234-237.CrossRefPubMed Papadopoulos NG, Dedoussis GV, Baxevanis CN, Papamichail M: Bioassay vs. immunoassay for quantification of interleukin-6 in biological fluids. Journal of Clinical Laboratory Analysis. 1995, 9: 234-237.CrossRefPubMed
40.
go back to reference Liu J, Li H, de Tribolet N, Jaufeerally R, Hamou MF, Van Meir EG: IL-6 stimulates growth and inhibits constitutive, protein synthesis-independent apoptosis of maurine B-cell hypridoma 7TD1. Cellular Immunology. 1994, 155: 428-435. 10.1006/cimm.1994.1135.CrossRefPubMed Liu J, Li H, de Tribolet N, Jaufeerally R, Hamou MF, Van Meir EG: IL-6 stimulates growth and inhibits constitutive, protein synthesis-independent apoptosis of maurine B-cell hypridoma 7TD1. Cellular Immunology. 1994, 155: 428-435. 10.1006/cimm.1994.1135.CrossRefPubMed
41.
go back to reference Krakauer T: A sensitive, specific immunobioassay for quantitation of human interleukin 6. Journal of Immunoassay. 1993, 14: 267-277.CrossRefPubMed Krakauer T: A sensitive, specific immunobioassay for quantitation of human interleukin 6. Journal of Immunoassay. 1993, 14: 267-277.CrossRefPubMed
42.
go back to reference Slim GC: Extracting glycogen from green shell mussels and the use of the glycogen as a food supplement or additive or in the treatment of inflammatory disease such as arthritis. 1998, New Zealand, Industrial Research Ltd. Slim GC: Extracting glycogen from green shell mussels and the use of the glycogen as a food supplement or additive or in the treatment of inflammatory disease such as arthritis. 1998, New Zealand, Industrial Research Ltd.
43.
go back to reference van den Berg WB: The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. Zeitschrift fur Rheumatologie. 1999, 58: 136-141. 10.1007/s003930050163.CrossRefPubMed van den Berg WB: The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. Zeitschrift fur Rheumatologie. 1999, 58: 136-141. 10.1007/s003930050163.CrossRefPubMed
44.
go back to reference Wilmore DW, Shabert JK: Role of glutamine in immunologic responses. Nutrition. 1998, 14: 618-626. 10.1016/S0899-9007(98)00009-4.CrossRefPubMed Wilmore DW, Shabert JK: Role of glutamine in immunologic responses. Nutrition. 1998, 14: 618-626. 10.1016/S0899-9007(98)00009-4.CrossRefPubMed
45.
go back to reference Lemire J: 1,25-Dihydroxyvitamin D3--a hormone with immunomodulatory properties. Zeitschrift fur Rheumatologie. 2000, 59: 24-27. 10.1007/s003930070034.CrossRefPubMed Lemire J: 1,25-Dihydroxyvitamin D3--a hormone with immunomodulatory properties. Zeitschrift fur Rheumatologie. 2000, 59: 24-27. 10.1007/s003930070034.CrossRefPubMed
46.
go back to reference Halpern GM: Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Allerg Immunol (Paris). 2000, 32: 272-278. Halpern GM: Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Allerg Immunol (Paris). 2000, 32: 272-278.
47.
go back to reference Tenikoff D, Murphy KJ, Le M, Howe PR, Howarth GS: Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. J Gastroenterol. 2005, 40: 361-365. 10.1007/s00535-005-1551-x.CrossRefPubMed Tenikoff D, Murphy KJ, Le M, Howe PR, Howarth GS: Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. J Gastroenterol. 2005, 40: 361-365. 10.1007/s00535-005-1551-x.CrossRefPubMed
48.
go back to reference Cho SH, Jung YB, Seong SC, Park HB, Byun KY, Lee DC, Song EK, Son JH: Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. Allerg Immunol (Paris). 2003, 35: 212-216. Cho SH, Jung YB, Seong SC, Park HB, Byun KY, Lee DC, Song EK, Son JH: Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. Allerg Immunol (Paris). 2003, 35: 212-216.
49.
go back to reference Gibson SL: The effect of a lipid extract of the New Zealand green-lipped mussel in three cases of arthritis. J Altern Complement Med. 2000, 6: 351-354. 10.1089/10755530050120727.CrossRefPubMed Gibson SL: The effect of a lipid extract of the New Zealand green-lipped mussel in three cases of arthritis. J Altern Complement Med. 2000, 6: 351-354. 10.1089/10755530050120727.CrossRefPubMed
50.
go back to reference Bierer TL, Bui LM: Improvement of arthritic signs in dogs fed green-lipped mussel (Perna canaliculus). J Nutr. 2002, 132: 1634S-6S.PubMed Bierer TL, Bui LM: Improvement of arthritic signs in dogs fed green-lipped mussel (Perna canaliculus). J Nutr. 2002, 132: 1634S-6S.PubMed
51.
go back to reference Bui LM, Bierer TL: Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Vet Ther. 2003, 4: 397-407.PubMed Bui LM, Bierer TL: Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Vet Ther. 2003, 4: 397-407.PubMed
52.
go back to reference Hill N, Sarvetnick N: Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol. 2002, 14: 791-797. 10.1016/S0952-7915(02)00403-X.CrossRefPubMed Hill N, Sarvetnick N: Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol. 2002, 14: 791-797. 10.1016/S0952-7915(02)00403-X.CrossRefPubMed
53.
go back to reference Hoozemans JJ, O'Banion MK: The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord. 2005, 4: 307-315. 10.2174/1568007054038201.CrossRefPubMed Hoozemans JJ, O'Banion MK: The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord. 2005, 4: 307-315. 10.2174/1568007054038201.CrossRefPubMed
Metadata
Title
In vitro modulation of inflammatory cytokine and IgG levels by extracts of Perna canaliculus
Authors
Sachin Mani
John W Lawson
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2006
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-6-1

Other articles of this Issue 1/2006

BMC Complementary Medicine and Therapies 1/2006 Go to the issue